Journal
ELECTROPHORESIS
Volume 44, Issue 1-2, Pages 62-71Publisher
WILEY
DOI: 10.1002/elps.202200140
Keywords
antibody-drug conjugates; CE; conjugation positions; disulfide exchange; product characterization
Ask authors/readers for more resources
Antibody-drug conjugates (ADCs) are a promising class of oncology therapeutics that can deliver cytotoxic drugs to specific locations. This study investigated the impact of disulfide bond reduction time on drug load and isomers of ADCs, revealing a dynamic relationship between them.
Antibody-drug conjugates (ADCs) are a prospective class of new oncology therapeutics with the ability to deliver a cytotoxic drug to a targeted location. The concept appears simple, but ADCs are highly complex due to their intrinsic heterogeneity. Randomly conjugated ADCs, for instance, are composed of conjugated species carrying between 0 and 8 linker-drug molecules, with several positional isomers that vary in drug distribution across the antibody. The drug load, expressed as drug-to-antibody ratio (DAR), is a critical quality attribute and should be well controlled, together with the distribution of drug molecules. Here, the impact of the duration of disulfide bond reduction on the DAR was investigated by quantitating the (isomeric) DAR species in ADCs produced with varying reduction times. Although hydrophobic interaction chromatography showed a constant DAR value as a function of reduction time, data obtained by non-reducing CE-SDS revealed an unexpected dynamic in the positional conjugated isomers. The insights obtained have improved our understanding of the correlation between the disulfide bond reduction, an important step in the manufacturing of a cysteine-conjugated ADC, and the conjugational heterogeneity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available